Tobacco settlement $ = biomedical research; business development

December 13, 2000

U-M awarded $47.8 million from Michigan tobacco settlement revenue for biomedical research and new business development.

The State of Michigan Life Sciences Corridor has awarded the first grants from tobacco settlement revenue to support life sciences research and economic development throughout the state. University of Michigan awards totaled $47.8 million.

U-M scientists were lead investigators in 24 of 58 research or commercial development proposals approved for funding by the Michigan Life Sciences Corridor steering committee in a Dec. 13 meeting in Lansing, Mich. In addition, U-M scientists will direct two of five advanced research centers for use by scientists from all Life Sciences Corridor institutions.

"Today's announcement is the result of a unique collaboration between Michigan's state government, its research institutions and its growing biotechnology industry," said Lee C. Bollinger, U-M president. "It is a tangible sign of the significance of today's life sciences revolution to our state's economy, the educational mission of its universities, and the profound impact the Corridor will have on medicine and society. Contributing to Michigan's leadership in life science research and new business development is in everyone's best interest."

The largest Life Sciences Corridor award will be used to develop a linked network of advanced technology laboratories in structural biology, proteomics, genomics, bioinformatics and animal models for researchers from universities, private research institutions, and biotechnology or pharmaceutical firms throughout Michigan. These core facilities will be physically located at the U-M, Michigan State University, Wayne State University or the Van Andel Institute, but they will be open to all scientists affiliated with the Life Sciences Corridor.

The U-M will house two of these facilities:

--The Michigan Proteome Consortium, to be established with $12 million in Life Sciences Corridor funding, will contain state-of-the-art technology to separate and identify proteins created by cells in response to genetic instructions.

--The Michigan Center for Biological Information, to be funded with a $9 million Life Sciences Corridor grant, will give scientists access to the advanced computing and bioinformatics resources they need to analyze and interpret massive amounts of complex data.

"We expect that establishment of and access to these facilities and technical services will attract biotechnology or biomedical companies and highly trained scientists to Michigan," said Gilbert S. Omenn, U-M executive vice president for medical affairs. "Sharing infrastructure will increase scientific collaboration and productivity, lead to more rapid applications for research discoveries in medicine, and jump start spin-off companies and licenses to existing companies."

"This research infrastructure proposal will catalyze the development of life science research and associated economic development in Michigan by making these cutting-edge technologies available to Michigan academic and industrial institutions involved in life science research or its applications," said Fawwaz T. Ulaby, U-M vice president for research.

Established with $1 billion from the state's tobacco lawsuit settlement, the Life Sciences Corridor was created to invest in and promote life sciences research and business development. The state of Michigan plans to award $50 million annually for 20 years to universities, research institutes and biotechnology companies. The initiative is administered by the Michigan Economic Development Corporation (MEDC).

Research or commercialization proposals from U-M scientists or companies marketing U-M technology that were approved for funding include:

--Developing more effective gene therapies for cancer.
--Learning how a key blood coagulation protein changes with age.
--Creation of a new biosensor to detect bacteria and viruses.
--Studying the effects of a "good" cholesterol protein on heart disease.
--Finding the gene for macular degeneration---one of the leading causes of blindness in older adults.
--Developing new high-resolution mammography technology.
--Clinical trials of a bioartificial kidney.
--Developing new drugs to treat heart attacks and cardiovascular disease.
--Testing a substance that kills bacterial, viral and fungal contaminants in food.
-end-
EDITORS: For related announcements from other Life Sciences Corridor institutions, contact: Sue Nichols at Michigan State University at 517-353-8942 or nichols@msu.edu; Casey Wondergem at Van Andel Institute at 616- 234-5390 or nancy.ward@vai.org; and Julie O'Connor at Wayne State University at 313-577-8845 or ag2712@wayne.edu.

The University of Michigan
News Service
412 Maynard
Ann Arbor, MI 48109-1399

University of Michigan

Related Biotechnology Articles from Brightsurf:

Cyanobacteria as "green" catalysts in biotechnology
Researchers from TU Graz and Ruhr University Bochum show in the journal ACS Catalysis how the catalytic activity of cyanobacteria, also known as blue-green algae, can be significantly increased.

Biotechnology to the rescue of Brussels sprouts
An international team has identified the genes that make these plants resistant to the pathogen that attacks crops belonging to the cabbage family all over the world.

UM professor co-authors report on the use of biotechnology in forests
University of Montana Professor Diana Six is one of 12 authors of a new report that addresses the potential for biotechnology to provide solutions for protecting forest trees from insect and pathogen outbreaks, which are increasing because of climate change and expanded global trade.

Faster genome evolution methods to transform yeast for industrial biotechnology
A research team led by Prof. DAI Junbiao at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences, in collaboration with Prof.

New innovations in cell-free biotechnology
Professor Michael Jewett's new platform to conduct cell-free protein synthesis could lead to improved quality of manufactured protein therapeutics and biomaterials.

Silk 'micrococoons' could be used in biotechnology and medicine
Microscopic versions of the cocoons spun by silkworms have been manufactured by a team of researchers.

The end of biotechnology as we know it
More than 400 attendees from five continents discussed trends and improvements in biotechnology at the European Summit of Industrial Biotechnology (ESIB) in Graz/Austria and talked many topics like a dehumanized research process.

Biotechnology: A growing field in the developing world
A detailed new report surveys a broad cross-section of biotechnology work across developing countries, revealing steady growth in fields tied to human well-being worldwide.

China releases first report on biotechnology in developing countries
The first report on biotechnology in developing countries revealing an overall picture of their biotechnology growth and competitiveness was released on Nov.

Exclusive: Biotechnology leaders surveyed about impact of Trump presidency
The day following the election of Donald J. Trump as President, a survey of leaders in biotechnology in the United States, conducted by Genetic Engineering & Biotechnology News showed that Trump's presidency will negatively impact NIH research funding as well as STEM education; a plurality said it will also spark a 'brain drain' as foreign-born researchers educated in American universities will be more likely to leave.

Read More: Biotechnology News and Biotechnology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.